Tamí-Maury et al.
[EXTRACT] Dear Editor,
Despite significant advancements in therapy and improved survival rates, gaps persist in achieving equal outcomes across the more than 100 lymphoma subtypes identified globally. In the United States (US) alone, the 5-year survival for non-Hodgkin lymphoma (NHL) rose from 62% in 2000 to 75% in 2017, and for Hodgkin lymphoma, from 82% to 90%, respectively (1). However, survival outcomes for virus-associated lymphomas have remained relatively stable in the US. [...]
Article's language
English
Letter